Sign in
IOBT Stock Price, Chart, Stats & News
IO Biotech, Inc.
Save
IO Biotech, Inc. (IOBT) does not currently pay a dividend.
885,690
Market cap
–
Current P/E
–
Forward P/E
IOBT chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | 1.07% |
ROA | -221.12% |
ROE | -465.36% |
D/E | 1.60x |
Interest coverage ratio | -80.82x |
IOBT valuation
P/E | – |
P/S | – |
P/B | 14.18x |
P/CF | -0.16x |
P/FCF | -0.17x |
P/OCF | -0.16x |
PEG | -0.01x |
EV multiple | -0.49x |
About
IO Biotech, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating immune-modulating cancer treatments. These therapies leverage its proprietary T-win technology platform. The company's primary investigational drug, IO102-IO103, is engineered to counteract immunosuppressive proteins such as Indoleamine 2,3-dehydrogenase (IDO) and programmed death-ligand (PD-L1).
Similar securities
Based on sector and market capitalization
Report issue